Linezolid is an oxazolidinone antibacterial drug, and its therapeutic drug monitoring and individualized treatment have been challenged since its approval. With the in-depth clinical research of linezolid, we have changed our attitude toward its therapeutic drug monitoring and our view of individualized treatment. On the basis of summarizing the existing clinical studies, and based on the practical experience of each expert in their respective professional fields, we have formed this expert consensus. Our team of specialists is a multidisciplinary team that includes pharmacotherapists, clinical pharmacology specialists, critical care medicine specialists, respiratory specialists, infectious disease specialists, emergency medicine specialists and more. We are committed to the safe and effective use of linezolid in patients in need, and the promotion of its therapeutic drug monitoring.

Lin, B., Hu, Y., Xu, P., Xu, T., Chen, C., He, L.e., et al. (2022). Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. FRONTIERS IN PUBLIC HEALTH, 10, 1-16 [10.3389/fpubh.2022.967311].

Expert consensus statement on therapeutic drug monitoring and individualization of linezolid

Federico, Pea;
2022

Abstract

Linezolid is an oxazolidinone antibacterial drug, and its therapeutic drug monitoring and individualized treatment have been challenged since its approval. With the in-depth clinical research of linezolid, we have changed our attitude toward its therapeutic drug monitoring and our view of individualized treatment. On the basis of summarizing the existing clinical studies, and based on the practical experience of each expert in their respective professional fields, we have formed this expert consensus. Our team of specialists is a multidisciplinary team that includes pharmacotherapists, clinical pharmacology specialists, critical care medicine specialists, respiratory specialists, infectious disease specialists, emergency medicine specialists and more. We are committed to the safe and effective use of linezolid in patients in need, and the promotion of its therapeutic drug monitoring.
2022
Lin, B., Hu, Y., Xu, P., Xu, T., Chen, C., He, L.e., et al. (2022). Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. FRONTIERS IN PUBLIC HEALTH, 10, 1-16 [10.3389/fpubh.2022.967311].
Lin, Bin; Hu, Yangmin; Xu, Ping; Xu, Tao; Chen, Chunyan; He, Le; Zhou, Mi; Chen, Zhangzhang; Zhang, Chunhong; Yu, Xuben; Fang, Luo; Zhu, Junfeng; Ji, ...espandi
File in questo prodotto:
File Dimensione Formato  
fpubh-10-967311.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 344.76 kB
Formato Adobe PDF
344.76 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/931316
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 14
social impact